4,5-二氨基-2-氟苯甲腈 | 226701-59-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4,5-二氨基-2-氟苯甲腈
• 英文名称: 2-fluoro-4,5-diaminobenzonitrile
• 英文别名: 4,5-diamino-2-fluorobenzonitrile
• CAS: 226701-59-3
• 化学式: C₇H₆FN₃
• 分子量: 151.143
• InChiKey: YSGFEOQZSGENDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,5-二氨基-2-氟苯甲腈 在 palladium on activated charcoal 盐酸 、 氢气 、 sodium thiosulfate 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 CRA-11092
  参考文献：
  名称：

  2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

  摘要：

  The development of potent and selective urokinase-type plasminogen activator (uPA) inhibitors based on the lead molecule 2-(2-hydroxy-3-ethoxyphenyl)-1H-benzimidazole-5-carboxamidine (3a) is described. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00311-6
• 作为产物：
  描述：

  2,4-二氟苯腈 在 palladium on activated charcoal 硫酸 、 氨 、 氢气 、 potassium nitrate 作用下， 生成 4,5-二氨基-2-氟苯甲腈
  参考文献：
  名称：

  2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

  摘要：

  The development of potent and selective urokinase-type plasminogen activator (uPA) inhibitors based on the lead molecule 2-(2-hydroxy-3-ethoxyphenyl)-1H-benzimidazole-5-carboxamidine (3a) is described. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00311-6

文献信息

• Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof
  申请人：MAILLIET Patrick

  公开号：US20080153837A1

  公开（公告）日：2008-06-26

  This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.

  这项发明涉及4-(苯并咪唑-2-基)芴和4-(氮杂苯并咪唑-2-基)芴的衍生物，涉及包含这些衍生物的药物组合物，以及涉及治疗与Hsp90蛋白活性相关的疾病的方法，包括给予这些衍生物。
• Compounds and compositions as anticoagulants
  申请人：Axys Pharmaceuticals, Inc.

  公开号：US06150379A1

  公开（公告）日：2000-11-21

  The present invention relates to novel biheterocyclic derivatives which are factor Xa inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新的双杂环衍生物，它们是Xa因子抑制剂；其药用盐和N-氧化物；它们作为治疗剂的用途以及其制备方法。
• Complement pathway modulators and uses thereof
  申请人：ADAMS Christopher Michael

  公开号：US20130296377A1

  公开（公告）日：2013-11-07

  The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物I的方法：制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合以及一种药物组成。
• HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Clasby Martin C.

  公开号：US20110065682A1

  公开（公告）日：2011-03-17

  The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

  本发明涉及公式I-III的新型杂环化合物，如本文所述或其药学上可接受的盐、溶剂化物、酯、前药或立体异构体。还揭示了包含该化合物的制药组合物，以及使用该化合物治疗或预防血栓栓塞性疾病的方法。
• Heterocyclic compounds as factor IXA inhibitors.
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2805939A1

  公开（公告）日：2014-11-26

  The present invention relates to novel heterocyclic compounds of Formulae I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

  本发明涉及式 I 的新型杂环化合物： 或其药学上可接受的盐、溶液剂、酯、原药或立体异构体。还公开了包含所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓栓塞性疾病的方法。